ArticleAntimicrobial agents and chemotherapy2003
Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Powerful bactericidal activity of moxifloxacin in human leprosy.Antimicrobial agents and chemotherapy · 2008Trial
- Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.Antimicrobial agents and chemotherapy · 2008Trial
- Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Immunomodulatory Effects and Protection in Sepsis by the Antibiotic Moxifloxacin.Antibiotics (Basel, Switzerland) · 2024Article
- The possible effect of topically applied azithromycin and moxifloxacin on the alleviation of uveitis.International ophthalmology · 2023Article
- Immunomodulatory and antimicrobial non-mulberryRSC advances · 2021Article
- Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions.JID innovations : skin science from molecules to population health · 2021Review
- Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes.Drugs in R&D · 2020Article
- Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.Therapeutic advances in chronic disease · 2019Review
- Hidradenitis suppurativa: infection, autoimmunity, or both?Therapeutic advances in musculoskeletal disease · 2019Review
- Moxifloxacin modulates inflammation during murine pneumonia.Respiratory research · 2014Article
- Efficacy of topically delivered moxifloxacin against wound infection by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2011Article
- Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2010Article
- Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Nursing home-acquired pneumonia: update on treatment options.Drugs & aging · 2006Review
- Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.Antimicrobial agents and chemotherapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of moxifloxacin, a new methoxyfluoroquinolone, on the production of proinflammatory cytokines from human peripheral blood mononuclear cells (PBMCs) were evaluated. Moxifloxacin inhibited the production of tumor necrosis factor alpha (TNF-alpha) and/or interleukin-6 (IL-6) by PBMCs stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), and heat-killed bacteria in a concentration-dependent manner without cytotoxic effects. The addition of moxifloxacin reduced the population of cells positive for CD-14 and TNF-alpha and for CD-14 and IL-6 among the LPS- or LTA-stimulated PBMCs. By Western blot analysis, moxifloxacin pretreatment reduced the degradation of IkappaBalpha in LPS-stimulated PBMCs. In conclusion, moxifloxacin could interfere with NF-kappaB activation by inhibiting the degradation of IkappaBalpha and reduce the levels of production of proinflammatory cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.